A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
DENVER, CO / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period...
In this discussion, we welcome Aytu BioPharma, NASDAQ ticker symbol AYTU. And with us today is their Chief Executive Officer, Josh Disbrow. This Fireside Chat was recorded during the Lytham Partners 2024 Investor Select Conference.
DENVER, CO / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings...
DENVER, CO / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings...
Webcasted presentation to take place at 1:10pm ETDENVER, CO / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be...
Q1 2024 Adjusted EBITDA of $2.2 millionRx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024Q1 2024 ADHD net revenue up 31% compared to Q1 2023$20.0 million cash balance at September 30, 2023Company to host conference call today at...
Ranked 118th Fastest Growing Company in North AmericaRanked 23rd Fastest Growing Life Sciences CompanyDENVER, CO / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics,...
DENVER, CO / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September...
U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract ManufacturerUpon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report Enhanced ADHD...
During this fireside chat we welcome Aytu BioPharma CEO Josh Disbrow. Aytu is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. This Fireside Chat was recorded during the Lytham Partners Fall...
ENGLEWOOD, CO / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings...
Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 millionRecord Q4 2023 total prescriptions increased 32% compared to Q4 2022Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million in Q4 2023Company to host conference call today at...
ENGLEWOOD, CO / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the...
ENGLEWOOD, CO / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the...
After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of ADHDENGLEWOOD, CO and GIVATAYIM, ISRAEL / July 31, 2023 / Aytu BioPharma, Inc. (the...
Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract ManufacturerUpon Completion of Manufacturing Transfer of Adzenys...
ENGLEWOOD, CO / June 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced Joshua Disbrow, Aytu's Chief Executive Officer, will participate in a...
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon ClosingPotential for Additional $7 Million in Event of Exercise of Common Warrants in FullExtends Interest Only Period on Avenue Capital Term Loan Through January 2025...
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon ClosingPotential for Additional $7 Million in Event of Exercise of Common Warrants in FullExtends Interest Only Period on Avenue Capital Term Loan Through January 2025...
Total prescriptions increased 32% compared to Q3 2022 to highest level in Company historyCompany to host conference call today at 4:30pm ETENGLEWOOD, CO / May 11, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and...
ENGLEWOOD, CO / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial...
ENGLEWOOD, CO / May 1, 2023 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, entered into an...
U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 2023Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Improve ADHD Product...
Second Consecutive Quarter of Positive Adjusted EBITDAQuarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx SegmentCompany to Host Conference Call Today at 5:00pm ETENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu")...
ENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
ENGLEWOOD, CO / February 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, has announced the...
ENGLEWOOD, CO / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
In this presentation, we welcome Aytu BioPharma, NASDAQ symbol AYTU, and with us today is their Chief Executive Officer, Josh Disbrow. Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics. This Fireside Chat...
ENGLEWOOD, CO / January 25, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced...
ENGLEWOOD, CO / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced...
Aytu RxConnect Providing Access Relief to Patients Amid Ongoing Generic Adderall® Supply DisruptionENGLEWOOD, CO / January 10, 2023 / Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them...
ENGLEWOOD, CO / January 5, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a...
Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall® XR Supply DisruptionAdzenys XR-ODT is the Only...
ENGLEWOOD, CO / November 22, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today...
Ranked 94th Fastest Growing Company in North AmericaRanked 21st Fastest Growing Life Sciences CompanyENGLEWOOD, CO / November 17, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing...
ENGLEWOOD, CO / November 16, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced the...
Record Quarterly Net Revenue of $27.7 Million Driven by 34% Growth in Rx SegmentPositive Adjusted EBITDA for the Quarter of $1.4 MillionLeadership Changes Implemented to Focus on Commercial OperationsCompany to Host Conference Call Today at 4:30pm ETENGLEWOOD, CO /...
ENGLEWOOD, CO / November 7, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
Amendment of Secured Loan Agreement Extends Interest-Only Period to January 2024Amendment Defers Over $3 Million in Principal Payments Beyond 2023Note Matures in January 2025, with Additional Extensions of the Interest-Only Period Available, Subject to Achievement of...
Following a corporate review, Aytu BioPharma is indefinitely suspending clinical development and removing expenses related to AR101/enzastaurin, Healight, and NT0502, and focusing on revenue growth and near-term cash flow generationAytu is expecting to generate...
This panel features three different companies that are looking to advance innovations in rare diseases or what are often designated by the FDA is orphan drugs. We have a diverse panel of participants that can hopefully each provide their own unique perspective on the...
In this presentation, we welcome Aytu BioPharma, NASDAQ ticker symbol of AYTU. And with us today is their Chief Executive Officer, Josh Disbrow. Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics. This...
ENGLEWOOD, CO / September 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, will report financial results for its fourth...
This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherited Vascular Disorders Including Vascular Ehlers-Danlos Syndrome (VEDS).Multiple Patent Families Filed in Key Global...
ENGLEWOOD, CO / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced that Aytu's management team will...
First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-Danlos SyndromeMultiple Patent Families Filed in Key Global MarketsENGLEWOOD, CO / August 16, 2022 / Aytu BioPharma, Inc....
ENGLEWOOD, CO / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten public offering...
ENGLEWOOD, CO / August 9, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814...
ENGLEWOOD, CO / August 8, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common...
ENGLEWOOD, CO / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Chief Executive Officer Josh Disbrow and Chief Financial Officer Mark Oki...